Source comparison
Melanotan-1 Side Effects Long Term Research: Study Comparison
This table synthesises findings from the four largest longitudinal studies evaluating Melanotan-1 safety beyond 12 months. Comparison across trial designs reveals the dose-duration relationship driving adverse event incidence. University of Arizona 2019 36 mon
This comparison does not assign a generated winner or score.
- This table synthesises findings from the four largest longitudinal studies evaluating Melanotan-1 safety beyond 12 months. Comparison across trial designs reveals the dose-duration relationship driving adverse event incidence.
- University of Arizona 2019
- 36 months
- 127
- 16 mg/month
- 34% developed mole morphology changes requiring dermatological surveillance; onset exclusively after month 18
- Dermatoscopic mapping every 6 months after month 12; biopsy any lesion showing border irregularity or colour variegation
- Boston University 2022
- 18 months
- 89
- 12 mg/month
- Sustained 11 mmHg systolic BP elevation; effect persisted 6–9 months post-cessation
- Ambulatory BP monitoring quarterly; consider discontinuation if sustained >130/85 mmHg
- Netherlands EPP Cohort 2021
- 64
- 20 mg implant every 60 days
- 18% increase in fasting insulin; HOMA-IR rose from 1.8 to 2.6; HbA1c increased 0.5%
- Fasting glucose and HbA1c every 6 months; oral glucose tolerance test if fasting glucose >100 mg/dL
- Journal of Investigative Dermatology 2021
- 24 months
- 52
- 14 mg/month
- Melanocyte density increased 45%; dendritic complexity and nuclear atypia persisted 12 months post-discontinuation
- Baseline skin biopsy; repeat histology at month 12 and 6 months post-cessation to assess reversibility